Behavioral Deficits and Striatal DA Signaling in LRRK2 p.G2019S Transgenic Rats: A Multimodal Investigation Including PET Neuroimaging

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Parkinson's Disease

• Publication date

  2014-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3233/JPD-140344PMID 25000966
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents

  2014cited by this paper
• Small animal PET imaging of the type 1 cannabinoid receptor in a rodent model for anorexia nervosa

  2014cited by this paper
• Investigating the effects of noise-induced hearing loss on serotonin transporters in rat brain using 4-[18F]-ADAM/small animal PET

  2013cited by this paper
• Non-Motor and Motor Features in LRRK2 Transgenic Mice

  2013cited by this paper
• PET Imaging of Serotoninergic Neurotransmission with [11C]DASB and [18F]altanserin after Focal Cerebral Ischemia in Rats

  2013cited by this paper
• Measuring dopaminergic function in the 6-OHDA-lesioned rat: a comparison of PET and microdialysis

  2013cited by this paper
• In-vivo Measurement of LDOPA Uptake, Dopamine Reserve and Turnover in the Rat Brain Using [18F]FDOPA PET

  2013influential reference
• Transient changes in the endocannabinoid system after acute and chronic ethanol exposure and abstinence in the rat: a combined PET and microdialysis study

  2013cited by this paper
• Leucine-Rich Repeat Kinase 2 (LRRK2)-Deficient Rats Exhibit Renal Tubule Injury and Perturbations in Metabolic and Immunological Homeostasis

  2013cited by this paper
• Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway

  2012cited by this paper
• The sensorimotor and cognitive deficits in rats following 90- and 120-min transient occlusion of the middle cerebral artery.

  2012cited by this paper
• (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD

  2012cited by this paper
• LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors

  2012cited by this paper
• In Vivo Dopamine Transporter Imaging in a Unilateral 6-Hydroxydopamine Rat Model of Parkinson Disease Using 11C-Methylphenidate PET

  2012cited by this paper
• Metabolic and type 1 cannabinoid receptor imaging of a transgenic rat model in the early phase of Huntington disease.

  2011cited by this paper
• Effects of Human Alpha-Synuclein A53T-A30P Mutations on SVZ and Local Olfactory Bulb Cell Proliferation in a Transgenic Rat Model of Parkinson Disease

  2011cited by this paper
• Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications

  2011cited by this paper
• Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice.

  2011cited by this paper
• Imaging biomarkers in Parkinson's disease.

  2011cited by this paper
• Use of [18F]FDOPA-PET for in vivo evaluation of dopaminergic dysfunction in unilaterally 6-OHDA-lesioned rats

  2011cited by this paper
• A Rat Model of Progressive Nigral Neurodegeneration Induced by the Parkinson's Disease-Associated G2019S Mutation in LRRK2

  2011cited by this paper
• A guide to neurotoxic animal models of Parkinson's disease.

  2011cited by this paper
• Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2

  2011cited by this paper
• Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity.

  2011cited by this paper
• Temporal Expression of Mutant LRRK2 in Adult Rats Impairs Dopamine Reuptake

  2011influential reference
• Enhanced Striatal Dopamine Transmission and Motor Performance with LRRK2 Overexpression in Mice Is Eliminated by Familial Parkinson's Disease Mutation G2019S

  2010cited by this paper
• Positron emission tomography kinetic modeling algorithms for small animal dopaminergic system imaging

  2010cited by this paper
• The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease

  2010cited by this paper
• Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice.

  2010cited by this paper
• Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of α-synuclein, and apoptotic cell death in aged mice

  2010cited by this paper
• Dopamine turnover increases in asymptomatic LRRK2 mutations carriers

  2010cited by this paper
• R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice

  2009influential reference
• Unexpected Lack of Hypersensitivity in LRRK2 Knock-Out Mice to MPTP (1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine)

  2009cited by this paper
• Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease

  2009cited by this paper
• Progression of dopaminergic dysfunction in a LRRK2 kindred

  2008cited by this paper
• Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study

  2008cited by this paper
• LRRK2 mutation in familial Parkinson's disease in a Taiwanese population: clinical, PET, and functional studies.

  2008cited by this paper
• Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands

  2007cited by this paper
• Performance Measurement of the microPET Focus 120 Scanner

  2007cited by this paper
• In Vivo Measurement of Density and Affinity of the Monoamine Vesicular Transporter in a Unilateral 6-Hydroxydopamine Rat Model of PD

  2007cited by this paper
• Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity.

  2007cited by this paper
• LRRK2 expression linked to dopamine‐innervated areas

  2006cited by this paper
• Kinase activity of mutant LRRK2 mediates neuronal toxicity

  2006cited by this paper
• Blockade of Nociceptin/Orphanin FQ Transmission Attenuates Symptoms and Neurodegeneration Associated with Parkinson's Disease

  2005cited by this paper
• Imaging the Dopamine System with In Vivo [11C]raclopride Displacement Studies: Understanding the True Mechanism

  2005cited by this paper
• Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations.

  2005cited by this paper
• PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.

  2005cited by this paper
• Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.

  2005cited by this paper
• Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT.

  2004cited by this paper
• Reproducibility of 11C-raclopride binding in the rat brain measured with the microPET R4: effects of scatter correction and tracer specific activity.

  2003cited by this paper
• Endogenous dopamine release after pharmacological challenges in Parkinson's disease

  2003cited by this paper
• Development and evaluation of an automated atlas-based image analysis method for microPET studies of the rat brain

  2003cited by this paper
• The neurobiology of slow synaptic transmission.

  2001cited by this paper
• A Reversible Tracer Analysis Approach to the Study of Effective Dopamine Turnover

  2001cited by this paper
• Intervention Strategies for Degeneration of Dopamine Neurons in Parkinsonism

  2000cited by this paper
• Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls.

  2000cited by this paper
• Homologous recombination based modification in Esherichia coli and germline transmission in transgenic mice of a bacterial artificial chromsome

  1997cited by this paper
• Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data

  1996cited by this paper
• A new PET ligand for the dopamine transporter: studies in the human brain.

  1995cited by this paper
• [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease

  1994cited by this paper
• Striatal binding of the PET ligand 11C‐raclopride is altered by drugs that modify synaptic dopamine levels

  1993cited by this paper
• Quantitation of Carbon‐11‐labeled raclopride in rat striatum using positron emission tomography

  1992cited by this paper
• Effects of endogenous dopamine on kinetics of [3H]N‐methylspiperone and [3H]raclopride binding in the rat brain

  1991cited by this paper
• [3H]Dihydrotetrabenazine, a new marker for the visualization of dopaminergic denervation in the rat striatum.

  1990cited by this paper

• Dopamine D2 receptor upregulation in dorsal striatum in the LRRK2-R1441C rat model of early Parkinson’s disease revealed by in vivo PET imaging

  2023cites this paper
• Modeling Parkinson’s disease in LRRK2 rodents

  2023cites this paper
• Content CN-21-5

  2023cites this paper
• The three sisters of fate: Genetics, pathophysiology and outcomes of animal models of neurodegenerative diseases.

  2022cites this paper
• Human Induced Pluripotent Stem Cell Phenotyping and Preclinical Modeling of Familial Parkinson’s Disease

  2022cites this paper
• PET imaging in animal models of Parkinson's disease.

  2022cites this paper
• Current and Emerging MR Methods and Outcome in Rodent Models of Parkinson’s Disease: A Review

  2021cites this paper
• Comprehensive Perspectives on Experimental Models for Parkinson’s Disease

  2021cites this paper
• Alpha-Synuclein and LRRK2 in Synaptic Autophagy: Linking Early Dysfunction to Late-Stage Pathology in Parkinson’s Disease

  2020cites this paper
• Linking the leucine-rich repeat kinase 2 gene, animal models, and Parkinson's disease

  2020cites this paper
• Signal transduction in Parkinson's disease: modulation of neurotransmission, symptomatology, and therapy

  2020cites this paper
• From Synaptic Dysfunction to Neuroprotective Strategies in Genetic Parkinson’s Disease: Lessons From LRRK2

  2020cites this paper
• Progress in LRRK2-Associated Parkinson’s Disease Animal Models

  2020cites this paper
• Translation Imaging in Parkinson’s Disease: Focus on Neuroinflammation

  2020influential citation
• CAV-2-Mediated GFP and LRRK2G2019S Expression in the Macaca fascicularis Brain

  2020cites this paper
• SocialWork 11-17-2017 Mitochondria : A Common Target for Genetic Mutations and Environmental Toxicants in Parkinson ’ s Disease

  2019cites this paper
• Sensory neuropathy and nociception in rodent models of Parkinson's disease

  2019cites this paper
• Lrrk2 alleles modulate inflammation during microbial infection of mice in a sex-dependent manner

  2019cites this paper
• New Developments in Genetic rat models of Parkinson's Disease

  2018cites this paper
• Evidence of Neurobiological Changes in the Presymptomatic PINK1 Knockout Rat

  2018cites this paper
• LRRK2 exonic variants associated with Parkinson’s disease augment phosphorylation levels for LRRK2-Ser1292 and Rab10-Thr73

  2018cites this paper
• Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson’s disease

  2018cites this paper
• Single Inflammatory Trigger Leads to Neuroinflammation in LRRK2 Rodent Model without Degeneration of Dopaminergic Neurons

  2018influential citation
• The unlikely partnership between LRRK2 and α‐synuclein in Parkinson's disease

  2018cites this paper
• Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.

  2017cites this paper
• Mitochondria: A Common Target for Genetic Mutations and Environmental Toxicants in Parkinson’s Disease

  2017cites this paper
• Models of LRRK2-Associated Parkinson's Disease.

  2017cites this paper
• LRRK2 mouse models: dissecting the behavior, striatal neurochemistry and neurophysiology of PD pathogenesis.

  2017cites this paper
• Early synaptic dysfunction in Parkinson's disease: Insights from animal models

  2016cites this paper
• LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function

  2016cites this paper
• Identification of candidate substrates of the leucine rich repeat kinase 2 by mass spectrometry-based phosphoproteomics

  2016cites this paper
• How Relevant Are Imaging Findings in Animal Models of Movement Disorders to Human Disease?

  2015cites this paper
• The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins.

  2015cites this paper
• Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.

  2015cites this paper
• [11C]PBR28 PET Imaging is Sensitive to Neuroinflammation in the Aged Rat

  2015cites this paper
• Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration*

  2015cites this paper